Samidorphan is a newly developed therapeutic agent used in the treatment of Prader-Willi Syndrome (PWS). PWS is a rare genetic disorder that is marked by obesity, learning disabilities, and behavioral problems. Samidorphan is an opioid antagonist that works by blocking the action of the opioid receptors in the brain, which helps to reduce food cravings and improve overall behavior in patients with PWS. Samidorphan is administered orally and is available as a tablet or a liquid solution. It is typically taken once daily and is typically used in combination with other treatments such as growth hormone therapy.
Samidorphan is a medication classified as an opioid antagonist. It's currently not available on its own, but it's combined with another medication called olanzapine (atypical antipsychotic) to create a single pill called Lybalvi. Lybalvi is approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar I disorder. The main benefit of samidorphan is that it helps reduce weight gain, which is a common side effect of olanzapine [1].
Here's how samidorphan works: opioid antagonists block the effects of opioid drugs like oxycodone or hydrocodone by attaching to opioid receptors in the brain. In the case of Lybalvi, samidorphan blocks opioid receptors that might be activated by olanzapine, reducing the olanzapine-induced weight gain [2].
Samidorphan is taken by mouth and should be used exactly as prescribed by your doctor [1]. It's important to note that samidorphan can cause side effects, including somnolence (sleepiness), dizziness, gastrointestinal issues, and hallucinations [3]